Position in LLY
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$63,609,376
+$18,345,655 QoQ
Shares Held
53,033
+7.8% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
3.49%
of 13F equity value
Holder Rank
#487
of 4,605 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026TRIGLAV INVESTMENTS, D.O.O. holds $143,400,994 across 9 Drug Manufacturers - General names. LLY ranks #1 (44.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
53,033 | $63,609,376 | |
| 2 | MRK |
Merck & Co., Inc.
|
193,541 | $24,870,018 | |
| 3 | JNJ |
Johnson & Johnson
|
84,162 | $21,374,623 | |
| 4 | ABBV |
AbbVie Inc.
|
47,600 | $11,978,064 | |
| 5 | PFE |
Pfizer Inc
|
333,000 | $8,018,640 | |
| 6 | AZN |
Astrazeneca PLC
|
38,280 | $7,258,653 | |
| 7 | BIIB |
Biogen Inc.
|
12,976 | $2,803,594 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
16,000 | $2,021,440 |
All Filings in LLY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $63,609,376 | 53,033 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $45,263,721 | 49,212 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $51,204,208 | 47,646 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $39,346,384 | 51,568 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $42,122,683 | 54,036 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $43,975,577 | 53,245 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $42,883,056 | 55,548 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||